AlphaYou
Overview
Smart money at a glance
Filings to Sep 27, 2026Net buying: insiders sold $0 and bought $3K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- +$3K netNet buying
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 5 added, 4 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 27- Open
- $166.16
- 52-wk high
- $209.11
- High
- $166.81
- 52-wk low
- $144.89
- Low
- $164.60
- Prev close
- $164.56
- Mkt cap
- $258.35B
- P/E
- 24.8x
- Volume
- 2.07M
- Fwd P/E
- 14.6x
- Beta
- 0.20
- Div yield
- 1.96%
- P/S
- 4.2x
- P/B
- 5.2x
- Profit margin
- +17.0%
- Op margin
- +23.5%
- ROE
- +22.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about AZN filings
Are insiders buying or selling AstraZeneca PLC (AZN) stock?
Net buying: insiders sold $0 and bought $3K of AZN stock on the open market in the 90 days to Sep 27, 2026, according to SEC Form 4 filings. The largest was Sharma, Mani (See Remarks), who bought $3K. The latest filing was on Sep 11, 2026.
Which members of Congress have traded AZN recently?
None. No member of Congress disclosed a AZN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this AZN smart-money data?
This summary uses filings available on Sep 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders are trading both ways.
What funds are doing
Buys/Adds (1)
- DS
D.E. Shaw
$202.6M
added
Sells/Trims (2)
- MI
Millennium
$146.6M
trimmed
- AL
Alger
$125.1M
trimmed
What insiders are doing
How top traders are positioned
No tracked top-trader positions in AZN right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 12.8% below what analysts expected.
Earnings per share
$2.50 expected
Reports Nov 5, 2026, in 39 days
Estimates as of Sep 27, 2026
EPS expected
$1.25 to $1.31
Revenue expected
11 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $15.19B | $15.50B | $15.29B | $15.38B |
| Cost of what it sold | $2.80B | $3.12B | $2.68B | $2.52B |
| Gross profit | $12.39B | $12.38B | $12.61B | $12.86B |
| What it spent | ||||
| Research and development | $3.66B | $3.86B | $3.49B | $4.05B |
| Sales and admin | $5.08B | $5.49B | $4.92B | $5.65B |
| Total operating expenses | $8.81B | $9.41B | $8.36B | $9.70B |
| What was left | ||||
| Operating profit | $3.58B | $2.98B | $4.25B | $3.16B |
| Interest on debt | $434.0M | $472.0M | $393.0M | $435.0M |
| Profit before tax | $3.24B | $2.63B | $3.91B | $2.80B |
| Tax | $709.0M | $300.0M | $833.0M | $291.0M |
| Net profit | $2.53B | $2.33B | $3.08B | $2.51B |
| EBITDA | $5.23B | $4.61B | $5.67B | $5.16B |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
75 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
AstraZeneca (AZN): Can Precision Medicine Offset a Narrower Breast Cancer Market?
Leans bearishSep 24AstraZeneca wins EU label expansion for Trixeo in asthma (AZN)
BullishSep 23AstraZeneca's Trixeo Secures Approval for Asthma in the EU
BullishSep 23EU clears first triple-therapy asthma medicine from AstraZeneca (AZN)
BullishSep 23REG - AstraZeneca PLC - Trixeo approved in EU for asthma
BullishSep 23AZN Historical Stock Prices & Daily Price Data | AstraZeneca PLC
NeutralSep 22AstraZeneca PLC (AZN) Stock Analysis: Is A 27.75% Upside On The Horizon?
BullishSep 22AstraZeneca (AZN) CEO buys 60,000 shares in LON trade
Leans bullishSep 19
Macro
20 macro signals shaping AZN right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results